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Abstract
Background: TCF7L2 polymorphisms have been consistently associated with type 2 diabetes mellitus in different
populations and type 2 diabetes mellitus is a major risk factor for cardiovascular disease, especially coronary artery disease.
This study aimed to evaluate the association between TCF7L2 polymorphism rs7903146 and coronary artery disease in
diabetic and non-diabetic subjects.
Methods and Results: two populations were studied in order to assess severity of coronary artery disease and
cardiovascular events incidence. Eight-hundred and eighty nine subjects who were referred for cardiac catheterization for
coronary artery disease diagnosis were cross-sectionally evaluated for coronary lesions (atherosclerotic burden) and 559
subjects from the MASS-II Trial were prospectively followed-up for 5 years and assessed for major cardiovascular events
incidence. As expected, rs7903146 T allele was associated with diabetes. Although diabetic patients had a higher
prevalence of coronary lesions, no association between TCF7L2 genotype and coronary lesions was found in this
subgroup. However, non-diabetic individuals carrying the T allele were associated with a significantly higher frequency of
coronary lesions than non-diabetic non-carriers of the risk allele (adjusted OR =2.32 95%CI 1.27–4.24, p=0.006).
Moreover, presence of multi-vessel coronary artery disease was also associated with the CT or TT genotypes in non-
diabetics. Similarly, from the prospective sample analysis, non-diabetics carrying the CT/TT genotypes had significantly
more composite cardiovascular end-points events than CC carriers (p=0.049), mainly due to an increased incidence of
death (p=0.004).
Conclusions: rs7903146 T allele is associated with diabetes and, in non-diabetic individuals, with a higher prevalence and
severity of coronary artery disease and cardiovascular events. name of registry site (see list below), registration number, trial
registration URL in brackets.
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Introduction
Diabetes mellitus (DM) is a common disease present in about
200 million of individuals worldwide and its prevalence has been
increasing [1]. People with DM have a higher risk of cardi-
ovascular (CV) complications, including coronary artery disease
(CAD). Actually, diabetes confers an equivalent risk to previous
myocardial infarction of future cardiovascular disease (CVD)
[2].
Genome-wide association studies have disclosed chromosomic
regions containing DM susceptibility genes in chromosome 10q,
which were later ascribed to intronic variations in the transcription
factor 7-like 2 (TCF7L2) gene and TCF7L2 variants have been
consistently associated with type 2 diabetes (T2D) in different
populations [3], including the Brazilian population [4]. In
addition, associations between TCF7L2 polymorphisms and other
conditions such as prostate, breast and colon cancers [5,6,7] and
even cardiovascular events [8] have been studied.
Thus, we aimed to study the association between the rs7903146
polymorphism, the most widely studied TCF7L2 genetic marker,
and CVD in individuals with and without diabetes. For this, we
have used two independent populations: 1) individuals referred to
cardiac catheterization for suspected coronary artery disease; 2)
individuals with established multivessel coronary artery disease
from the MASS-II Trial (ISRCTN66068876), whom were
followed-up for 5 years for CV events incidence (all cause
mortality, myocardial infarction, recurrent angina, and new
cardiac procedures).
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Patient populations
Individuals referred for cardiac catheterization for the
diagnosis of CAD. A cross-sectional study of severity of
coronary artery disease was performed at the Laboratory of
Hemodynamic of the Heart Institute (InCor), Sa ˜o Paulo, Brazil.
All patients had a suspected clinical diagnosis of angina pectoris
and stable angina and no patient enrolled in this study was
currently experiencing an acute coronary syndrome. Patients with
previous cardiac events and/or previous diagnostic or therapeutic
coronary catheterization, acute ischemic events, heart failure class
III–IV, hepatic dysfunction, familiar hypercholesterolemia,
previous heart or kidney transplantation, and in anti-retroviral
treatment were excluded from the study. Of a total of 1,451
patients consecutively seen, 167 were excluded because they have
been previously submitted to cardiac bypass surgery, 140 were
excluded because they have already received coronary stents, 78
have been previously submitted to angioplasty, 163 due to a
diagnostic cardiac catheterism before this evaluation and 7
because of genotyping missing data. The coronary lesions were
evaluated by an expert team by analyzing angiogram images,
based on standard protocols. Patients answered a clinical
questionnaire that covered questions regarding their personal
medical history, family history of CAD, sedentary behavior,
smoking status, hypertension, obesity, dyslipidemia, diabetes, and
current medical treatment. During the interview, anthropometric
measures were collected (weight and height), and a blood sample
during cardiac catheterization for genomic DNA extraction was
obtained. All patients signed an informed consent form and the
study has been approved by the Ethics Committee of the Heart
Institute of the University of Sao Paulo-Brazil (research protocol #
1081/07).
MASS II Study population. The participants of this second
population were selected from the prospective, randomized,
controlled clinical trial MASS II. The MASS II trial was
designed to compare medical treatment, angioplasty/stent
placement, and surgical myocardial revascularization in patients
with stable multivessel CAD with preserved left ventricular
function. Briefly, 2,076 candidates who were indicated for
myocardial revascularization were evaluated from May, 1995 to
May, 2000. Of these, 611 patients were eligible and met all entry
criteria to be randomly assigned to one of the three therapeutic
groups. The inclusion criteria were symptomatic multivessel
coronary disease, preserved left ventricular function, and the
presence of coronary lesions (70% of stenosis) amenable to
angioplasty. Then patients were followed-up for five years and
were assessed for cardiovascular events such as mortality,
myocardial infarction, angioplasty, myocardial revascularization
surgery and the combination of them. All patients from the
MASS-II study were repeatedly evaluated in a single-center (Heart
Institute, Brazil) by the same medical team for the five years of
follow-up, according to a standard protocol. All events (except
non-hospital deaths) were preferentially attended at the Heart
Institute [9,10,11].
All patients signed an informed consent form and the study has
been approved by the Ethics Committee of the Heart Institute of
the University of Sao Paulo-Brazil (research protocol # 1081/07).
Coronary artery disease severity score
A score was created in order to assess the severity of the CAD.
Twenty coronary segments were analyzed for the construction of
the score. Each epicardial vessel or main branch was divided into 3
segments (proximal, medial and distal) except secondary branches
of the right coronary artery that were divided in 2 segments,
proximal and distal. The score was defined as the sum of each
coronary segment analyzed: no lesion or irregularities — 0 points,
less than 50% lesion — 0.3 points, 50–70% lesion — 0.6 points,
70–90% lesion — 0.8 points and 90–100% lesion — 0.95 points.
Use and characteristics of this score has been previously described
[12].
TCF7L2 rs7903146 polymorphism genotyping
Genomic DNA was extracted from peripheral blood leukocytes
by means of a standard salting-out procedure. PCR primers used
were: 59 ACA ATT AGA GAG CTA AGC ACT TTT TAG
GTA 39 and 59 GTG AAG TGC CCA AGC TTC TC 39. The
studied polymorphism was detected by polymerase chain reaction-
restriction fragment length polymorphism assay (PCR-RFLP).
Briefly, a 30-cycle PCR was carried out in a PTC-DNA Engine
Tetrad2 using a 10 mL reactive solution containing 10 mM Tris-
HCl (pH 9.0), 50 mM KCl, 2.5 mM MgCl2, 100 mM of each
dNTP, 0.3 U Easy Taq DNA Polymerase, 5 pmol of each primer
and 1 mL of genomic DNA template. PCR products were digested
with 1 U of RsaI restriction enzyme and visualized by 3% agarose
gel electrophoresis. The quality control for these assays was
assessed by randomly selecting 40 samples that were re-genotyped
by an independent technician. Observed concordance between
genotyping assays was 100%.
Statistical analysis
Hardy–Weinberg equilibrium for the distribution of genotypes
was estimated by the Chi-square test. Chi-square tests, t-tests, and
analysis of variance were used for baseline comparisons. The odds
ratios for different association models were calculated with 95%
confidence interval (CI) by multiple logistic regression with
confounders determined by a backward conditional elimination
method for a significance level below 0.05. Long-term survival
comparisons were conducted for the entire study group and for the
subgroups of diabetic and non-diabetic patients and TCF7L2
genotype. Logistic regression was used to estimate the cross-
sectional association of these variables with each of the MASSII
trial endpoints (death, myocardial infarction, and recurrent
ischemia requiring revascularization), as well as the combined
endpoint after the 5-year follow-up period. Survival curves were
calculated with the Kaplan-Meier method, and differences
between the curves were evaluated with the log-rank statistic.
We assessed the relationship between baseline variables and
composite end points by using a Cox proportional hazards survival
model. A value of p,0.05 was considered significant for
comparisons. SPSS version 13 program for Windows was used
for statistical analysis.
The authors had full access to the data and take responsibility
for its integrity. All authors have read and agree to the manuscript
as written.
Results
Cross-sectional analysis - Assessment of CAD Severity
In this first part, we studied a population referred for cardiac
catheterization for the diagnosis of CAD at the Laboratory of
Hemodynamics, InCor, Brazil. Eight hundred and ninety six
consecutive patients submitted for the first time only to coronary
angiography to study a clinical suggestive diagnosis of coronary
artery disease were selected. This study population had 52.4% of
male individuals, with a mean age of 59.5 years. The prevalence of
hypertension, diabetes, obesity (BMI .30.0 kg/m
2), smoking,
heart failure (HF) class I-II, peripheral artery disease (PAD) and
TCF7L2 and CAD
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9.2% and 2.7%, respectively. The mean values of fasting glycemia,
total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycer-
ides measurements were 130.2 mg/dl, 229.0 mg/dl, 145.0 mg/dl,
44.8 mg/dl and 181.4 mg/dl, respectively.
In the entire population, the rs7903146 genotype frequencies
were: CC =46.8% (n=419); CT =42.6% (n=382); TT =
10.6% (n=95). For the CC, CT and TT genotypes, respectively,
the prevalence of diabetes was 32.2%, 30.9% and 36.8%. There
was no difference in genotype frequencies for age, sex, smoking,
BMI, total cholesterol, HDL- and LDL-cholesterol, triglycerides or
systolic and diastolic blood pressure, hypertension, APD, HF and
CRF.
Although clinically suspected, 267 patients had no identifiable
coronary lesions by angiography. As expected, diabetic patients
had a higher prevalence of obstructive coronary lesions (,80% of
individuals), independent of the genotype they carry (p=0.93).
Although there were no differences in the prevalence of coronary
lesions between the three TCF7L2 genotypes in the entire
population, non-diabetic patients that carried allele T (non-
diabetics CT and TT individuals) had a significantly higher
frequency of coronary lesions as compared to non-diabetic
individuals with the CC genotype. Allelic analysis also revealed a
significant association between allele T and coronary lesions in this
subgroup (OR =1.37 per allele, 95%CI =1.05–1.78, p=0.025).
The demographic and laboratorial characteristics of non-carries of
T allele and carries are shown in Table 1. The individuals CT/TT
had an almost 2.5 fold higher chance of having obstructive
coronary lesions when compared to group 1 (Table 2). This
increased odd of having an increased atherosclerotic burden was
still present even after adjustment for age, sex, BMI, smoking,
hypertension, glycemia, total cholesterol, LDL-c, HDL-c and
triglycerides and use of statins, aspirin and beta-blockers.
Regarding atherosclerosis burden, non-diabetic carriers of the T
allele had a significantly higher chance of having any coronary
lesion (OR 1.51, p=0.01); a significantly higher prevalence of
three-vessel coronary disease as opposed to having normal
coronary arteries (OR 1.76, p=0.01) (Table 3). In addition,
considering the severity score divided in tertiles, having the CT or
TT genotypes was also associated with an increased odd of being
in the second or third tertile of atherosclerosis burden (Table 4). By
linear regression, the presence of one T allele increased the score
Table 1. Demographic and laboratorial characteristics of non-diabetic and diabetic subjects from the cross-sectional population
according to TCF7L2 genotype.
Non-diabetic subjects Diabetic Subjects
CC (n=284) CT + TT (n=324) P value* CC (n=135) CT+TT (n=153) P value*
Age (years) 58.4611.1 59.4610.4 0.229 61.069.6 60.369.4 0.507
Male gender (%) 53.5 57.1 0.376 45.9 46.4 0.935
Smoking (%) 35.6 41.7 0.123 29.6 36.6 0.210
Sedentarism (%) 94.0 90.1 0.214 94.8 93.5 0.303
BMI (kg/m
2) 27.865.3 27.364.6 0.087 28.965.5 28.665.4 0.672
Hypertension (%) 70.1 65.7 0.254 80.7 86.3 0.205
Congestive Heart Failure (%) 10.2 8.6 0.508 6.7 15.7 0.016
Chronic Kidney Disease (%) 1.8 1.5 0.770 5.2 3.9 0.755
Glucose (mg/dL) 104.2621.1 103.9619.2 0.288 172.1669.1 177.7673.2 0.522
Total cholesterol (mg/dL) 229.1647.3 230.3653.3 0.510 231.2647.4 223.9647.0 0.248
LDL-c (mg/dL) 145.4638.5 147.1643.1 0.698 154.0642.3 132.4641.2 0.002
HDL-c (mg/dL) 46.0613.4 44.7612.9 0.577 42.9610.4 44.6613.0 0.394
Triglycerides (mg/dL) 164.76104.5 163.36102.5 0.831 223.46192.5 210.26188.1 0.602
(*) Comparison between genotypes groups in non-diabetic and diabetic subjects, calculated by chi-square test for categorical variables and by t-student test for
continuous variables; BMI - body mass index.
doi:10.1371/journal.pone.0007697.t001
Table 2. Prevalence and risk estimative of coronary lesions according to TCF7L2 genotype.
Genotypic groups Prevalence (n) OR Adjusted OR* P value
Diabetic subjects CC 80.7% (109) 1.00 - 0.727
CT+TT 79.1% (121) 0.902 (0.51–1.61) -
Non-diabetic subjects CC 60.6% (172) 1.00 1.00 0.006{
CT+TT 70.1% (227) 1.52 (1.09–2.13) 2.32 (1.27–4.24)
All subjects CC 67.1% (281) 1.00 1.00 0.112{
CT+TT 73.0% (348) 1.325 (0.99–1.76) 1.47 (0.91–2.36)
(*) Adjusted for sex, BMI, smoking, hypertension, glycemia, total cholesterol, LDL-c, HDL-c, triglycerides.
({) p value for adjusted OR.
doi:10.1371/journal.pone.0007697.t002
TCF7L2 and CAD
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(p=0.038). After adjustment for potential confounders, including
glycemia, some, but not all, unadjusted comparisons were no
longer statistically significant (Tables 3 and 4).
Prospective Analysis - Incidence of Cardiovascular Events
in the MASS-II Trial
In order to evaluate if TCF7L2 genotype was also associated
with cardiovascular events in a population of individuals already
with extensive coronary artery disease, we studied the patients
from the MASS-II Trial. This study population included 559
eligible individuals, of whom 69.2% were male, with a similar
mean population age of 59.7 years and mean BMI of 27.1 kg/m
2.
Hypertension was present in 59.6%, diabetes in 30.9% and
smoking in 33.9% of studied individuals. The mean value of
fasting glycemia, total cholesterol, LDL-cholesterol, HDL-choles-
terol and triglycerides measurements were 129.6 mg/dl,
223.4 mg/dl, 147.5 mg/dl, 37.3 mg/dl and 194.0 mg/dl, respec-
tively. Genotype counts and frequency were as follow: CC =159
(28.4%), CT =336 (60%), and TT =65 (11.6%). The
characteristics of carriers of T allele and non-carriers patients
are shown in Table 5.
Kaplan-Meier curve analysis is shown in Figure 1. The group
with rs7903146 genotype CT or TT was associated with a
significantly higher incidence of cardiovascular events (Figure 1A).
In absolute values, CT/TT group had 47 composite events,
compared to 12 events in the CC group. However, it can be
observed that the TCF7L2 polymorphism is not associated with
the composite end point of cardiovascular events (cardiac death,
myocardial infarction, and refractory angina requiring revascular-
ization or new cardiac catheterization) in diabetic subjects
(Figure 1B). Decompounding the end points in non-diabetic
individuals, we observed that the association between TCF7L2
genotype and cardiovascular events occurred mainly because an
increased all-cause mortality incidence in individuals harboring the
T allele (number of deaths: CT/TT =27 vs CC =4, p value =
0.004). Although incidence of myocardial infarction, myocardial
revascularization, percutaneous coronary intervention (PCI) and
stroke were higher in CT/TT group in non-diabetics, we were not
able to reach statistical significance (p.0.10). Finally, after
adjustment for several established risk factors for cardiovascular
disease listed in Table 5, only TCF7L2 genotypes CT or TT
(p=0.047), age (p=0.003) and smoking (p=0.013) were signifi-
cantly and independently associated with cardiovascular events
incidence.
Discussion
The study data showed a significant association between
TCF7L2 rs7903146 genotypes and coronary artery disease in
non-diabetic individuals, in both independent populations.
Interestingly, we were not able to demonstrate this association in
diabetic patients.
It has been well established for many decades that diabetes
increases the risk of CVD. About 65% of deaths in individuals with
type 2 diabetes are related to heart disease or stroke [13,14]. These
data are concordant with the results of this study, in which diabetic
individuals had a higher severity of CAD and cardiovascular
events incidence than non-diabetics. Considering this information
and since there were no associations between rs7903146
polymorphism and established CV risk factors, other than diabetes
itself, we hypothesize that the association between TCF7L2
genotype and cardiovascular phenotypes occurs due to glycemic
homeostasis changes. Nevertheless, given the scenario of estab-
lished diabetes, coronary disease risk will be increased by itself,
despite TCF7L2 genotype status.
Genetic variants in the gene encoding for TCF7L2 have been
associated with type 2 diabetes and impaired cell function, but the
mechanisms still remain unknown. The gene TCF7L2 is located
on chromosome 10 and encodes the transcription factor4 (TCF-4)
and single nucleotide polymorphism (SNP) rs7903146 strongly
predicts prevalent and future T2DM in several independent
populations [3]. The risk T allele was associated with impaired
Table 3. Distribution of coronary lesions in non-diabetic patients with coronary lesions according to genotypes.
CC % (n) CT + TT % (n) OR* P value Adjusted OR{ P value{
Normal 43.7 (124) 34.0 (110) 1.00 1.00
One-vessel disease 20.8 (59) 27.8 (90) 1.72 (1.13–2.61) 0.01 2.09 (1.08–4.04) 0.03
Two-vessel disease 19.4 (55) 16.0 (52) 1.07 (0.67–1.68) 0.79 1.47 (0.75–2.90) 0.26
Three-vessel disease 16.2 (46) 22.2 (72) 1.76 (1.12–2.77) 0.01 2.06 (1.00–4.25) 0.05
(*) Odds Ratio calculated by comparison between one-vessel, two-vessel, and three-vessel disease versus normal coronary arteries by multiple logistic regression.
({) Adjusted for sex, BMI, smoking, hypertension, glycemia, total cholesterol, LDL-c, HDL-c, triglycerides and use of statins, aspirin and beta-blockers; ({) p value for
adjusted OR.
doi:10.1371/journal.pone.0007697.t003
Table 4. Tertile distribution of severity artery coronary lesions score (SCS) in non-diabetic patients according to TCF7L2 genotypes.
CC % (n) CT + TT % (n) OR* P value Adjusted OR{ P value{
1st Tertile (#0.9) 38.7 (110) 28.4 (92) 1.00 1.00
2
nd Tertile (0.91–2.2) 29.9 (85) 36.1 (117) 1.65 (1.11–2.44) 0.01 1.004 (0.53–1.91) 0.99
3
rd Tertile ($2.2) 31.3 (89) 35.5 (115) 1.55 (1.04–2.28) 0.03 1.31 (0.69–2.47) 0.40
(*) Odds Ratio calculated by comparison between tertiles by multiple logistic regression (reference group first tertile).
({) Adjusted for sex, BMI, smoking, hypertension, glycemia, total cholesterol, LDL-c, HDL-c, triglycerides, use of statins, aspirin and beta-blockers; ({) p value for adjusted
OR.
doi:10.1371/journal.pone.0007697.t004
TCF7L2 and CAD
PLoS ONE | www.plosone.org 4 November 2009 | Volume 4 | Issue 11 | e7697insulin secretion and incretin effects [15], trending to postprandial
hyperglycemia. Data from MONICA/KORA surveys revealed
the T allele at rs7903146 as inversely associated with log-
transformed HOMA-%Beta (as a measure of basal insulin
secretion), but no association was found with insulin resistance
and metabolic syndrome. Therefore, we hypothesize that even
non-diabetic carriers of CT/TT genotypes have increased
postprandial glycemia and consequently, higher CAD tendency,
severity and cardiovascular events incidence.
Actually, a meta-analysis of published data from 20 studies with
almost 100,000 subjects followed-up for 12.4 years confirmed a
significant association between 2-hour glucose levels after an oral
glucose overload and incident cardiovascular events [16]. In this
same study, there was a suggestive trend (p value equal to 0.056)
between fasting glucose and cardiovascular events. These data
support the hypothesis that even non-diabetic degrees of fasting
and mainly postprandial hyperglycemia are associated with CVD.
Therefore, if T allele is associated with postprandial hyperglyce-
mia, we hypothesized T allele would be associated with
cardiovascular events. Plasma glucose is a continuous risk factor
for CVD, in both diabetic and non-diabetic people, the risk
extending below impaired fasting and impaired glucose tolerance
Table 5. Demographic and laboratorial characteristics of non-diabetic subjects from the MASS-II population according to TCF7L2
genotype.
Non-diabetic subjects Diabetic subjects
CC (n=120) CT + TT (n=266) P value* CC (n=38) CT + TT (n=135) P value*
Age (years) 59.669.2 59.169.4 0.836 62.766.4 59.869.1 0.071
Male gender (%) 68.3 71.4 0.537 60.5 65.2 0.280
Smoking (%) 34.2 36.5 0.663 31.6 25.9 0.479
BMI (kg/m
2) 27.663.9 26.464.0 0.966 27.964.4 28.064.6 0.880
Hypertension (%) 56.7 53.8 0.595 73.7 66.7 0.673
Previous MI (%) 39.2 50.0 0.048{ 26.3 45.9 0.030
Glucose (mg/dL) 104.0617.4 107.2621.3 0.551 161.3663.6 183.0679.7
Total cholesterol (mg/dL) 220.5644.4 225.9648.3 0.409 221.0649.6 219.2650.6 0.848
LDL cholesterol (mg/dL) 147.3638.2 149.9644.7 0.349 144.7641.9 141.2646.8 0.688
HDL cholesterol (mg/dL) 37.569.4 37.0610.7 0.783 37.2611.9 38.1610.6 0.673
Triglycerides (mg/dL) 186.26109.9 185.0694.6 0.191 213.36156.2 205.46141.5 0.765
(*) calculated by qui-square test for categorical variables and by t-student test for continuous {variables; ({) p value ,0.05; BMI - body mass index; MI - myocardial
infarction.
doi:10.1371/journal.pone.0007697.t005
Figure 1. Kaplan-Meier Curve of TCF7L2 genotypes and composite cardiovascular end points in non-diabetic (A) and diabetic
patients (B) after 5 years of follow-up. In non-diabetic patients, individuals CT and TT had a significant higher incidence of composite
cardiovascular endopoints (death, non-fatal myocardial infarction, refractory angina requiring revascularization or new cardiac catheterization – PCI).
Although diabetic individuals had a higher incidence of cardiovascular events than non-diabetics, a presence of T allele was not associated with
cardiovascular endpoints.
doi:10.1371/journal.pone.0007697.g001
TCF7L2 and CAD
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added to the list of established continuous cardiovascular risk
factors [17]. Most cardiovascular risk factors are affected directly
by an acute increase of glycemia: increase in LDL oxidation and
endothelial dysfunction (vasoconstriction and decreased vasodilat-
ing response), increased production of collagen from the mesangial
cell, activation of blood coagulation, increase in blood pressure,
increase in the circulating levels of intracellular adhesion molecule
1 (ICAM-1), increase in inflammation (production of plasma
interleulin-6, interleukin-18 and tumor necrosis factor-a - TNF-a)
and increase in oxidative stress [17,18]. Unfortunately, there was
no information about glycated haemoglobin or postprandial
glycemia in our study and we were not able to evaluate this
correlation. Regarding fasting glycemia, there is no difference
between genotypes in non-diabetic individuals, but we were not
able to evaluate the effects of the studied genotype in longitudinal
glucose-related variables. In addition, after adjustment for other
established cardiovascular risk factors, including baseline fasting
glycemia, genotypes CT and TT continued to be related to CAD
severity and CV events, mainly death.
Moreover, some studies have observed that transcriptional
activation of TCF-4 is related to the nuclear factor-kB (NF-kB)
signaling pathway, which regulates inflammatory signaling
pathways [19] and this could be hypothesized as an additional
pleiotropic mechanism operant in the milieu of the vascular wall.
It should be remembered that the diabetic subgroups from both
populations have a smaller number of individuals and one can not
exclude that this small number of individuals associated with the
higher prevalence of coronary artery disease and incidence of
cardiovascular events in this particular subgroup of individuals has
led to reduced statistical power to detect the association we were
able to describe on non-diabetic individuals. However, even a
relatively small sample size of non-diabetic subjects was able to
provide an adequate statistical power analysis, in part due to the
relatively large effect size. Despite this, it is not possible to exclude
completely the possibility of false positive results. Considering it is
a genetic study of association, a limitation is the possibility of other
non evaluated variable that, by acting as a confounder, could play
a significant role in the findings. One should remember, however,
that multiple potential confounder adjustments were made in the
presented analysis. Finally, results in the same direction in two
different and independent populations may actually be indicative
of a true association.
Previous myocardial infarction was significantly more prevalent
in genotypes CT and TT in non-diabetic individuals from the
MASS-II population. However, this factor was not independently
associated with CV events, like TCF7L2 genotype, smoking and
aging. Therefore, the higher prevalence of a previous myocardial
infarction at baseline does not completely explain such association.
Actually, these data contribute to the idea that non-diabetic
patients carriers of the rs7903146 allele T presents a higher CAD
severity.
Bielinski et al [8] have recently published a study in which
TCF7L2 SNPs rs7903146, rs12255372, rs7901695, rs11196205
and rs7895340 were assessed with a similar objective, using more
than 13,000 subjects from the ARIC study population. In their
report, they have not demonstrated a significant association
between any TCF7L2 SNP with incident coronary disease,
ischemic stroke, CVD, prevalent peripheral artery disease (PAD)
or all-cause mortality in the full cohort nor when stratified by race
or diabetic status. Although divergent results, there are large
methodological differences between the two studies: in the ARIC
study, all patients with prevalent coronary disease were excluded
from analysis and, consequently, the patients were free of
prevalent CVD at baseline. On the other hand, our study
populations contain patients with suspected CAD (cross-sectional
study population) or with established multi-vessel CAD plus stable
angina (MASS-II cohort) at baseline and these differences in the a
priori risk of coronary artery disease in these populations could
explain the apparent conflicting results. Here as well, it should be
acknowledged that the interpretations of the present study are
derived from two different and independent cohorts of patients,
straightening the conclusions of the present work.
In conclusion, these data demonstrate an association between
coronary artery disease severity and rs7903146 polymorphism
mainly in non-diabetic individuals with increased cardiovascular
risk. In people with diabetes, we were not able to show this
association. Additionally, it was found that non-diabetic allele T
carriers also had higher cardiovascular event incidence, mainly
due to death. Due to the limitations already discussed, more
studies are necessary to confirm this association and to evaluate
the intrinsic mechanisms underlining this process. If this
association is confirmed, other studies will also be useful to
establish the best strategy to use this information for the better risk
stratification of individuals.
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